Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
Clinical trial NCT03047083 · COMPLETED
Trial details
- NCT number
- NCT03047083
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2014-06-02
- Primary completion
- 2016-03-18
- Enrollment
- 1027
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.